+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07391657

Comparing AZD0120 Dual-Targeted CAR-T Cell Therapy Versus Standard Treatments in Relapsed Refractory Multiple Myeloma

Led by AstraZeneca · Updated on 2026-09-29

508

Participants Needed

143

Research Sites

110 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating AZD0120, a dual-targeted CAR-T cell therapy against BCMA and CD19, compared with standard treatment regimens in people with relapsed refractory multiple myeloma RRMM. This Phase III open-label, randomized global trial aims to compare the effectiveness and safety of AZD0120 against four standard regimens DKd daratumumab, carfilzomib, dexamethasone, DPd daratumumab, pomalidomide, dexamethasone, PVd pomalidomide, bortezomib, dexamethasone, and Kd carfilzomib, dexamethasone. Participants will be randomly assigned to receive either AZD0120 or one of the four standard regimens chosen by their investigator. AZD0120 is a biological CAR-T cell therapy, while the standard regimens involve combinations of drugs administered according to routine care. The study evaluates treatment effectiveness over several years, including progression-free survival and minimal residual disease negativity. During the trial, participants will undergo regular assessments including laboratory tests and clinical evaluations to monitor disease status and treatment response. Key outcomes include progression-free survival and minimal residual disease negativity rates. Safety and effectiveness will be monitored over multiple years. The total study duration extends up to 5 years, with participants followed for outcomes such as overall survival and response rates.

CONDITIONS

Brief Title

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here